Public Employees Retirement System of Ohio Sells 2,443 Shares of Elevance Health, Inc. $ELV

Posted by Geri Gentry on Jul 25th, 2026

Public Employees Retirement System of Ohio decreased its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 2.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 98,981 shares of the company’s stock after selling 2,443 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Elevance Health were worth $28,977,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ELV. Liberty One Investment Management LLC lifted its stake in Elevance Health by 1,450.0% in the 1st quarter. Liberty One Investment Management LLC now owns 930 shares of the company’s stock valued at $272,000 after purchasing an additional 870 shares during the last quarter. Bank of Nova Scotia grew its stake in shares of Elevance Health by 77.9% during the first quarter. Bank of Nova Scotia now owns 237,998 shares of the company’s stock worth $69,674,000 after buying an additional 104,212 shares during the last quarter. Sei Investments Co. grew its stake in shares of Elevance Health by 14.3% during the first quarter. Sei Investments Co. now owns 204,457 shares of the company’s stock worth $59,854,000 after buying an additional 25,631 shares during the last quarter. Cetera Investment Advisers increased its holdings in shares of Elevance Health by 19.8% during the first quarter. Cetera Investment Advisers now owns 97,014 shares of the company’s stock worth $28,401,000 after buying an additional 16,058 shares in the last quarter. Finally, WealthCollab LLC increased its holdings in shares of Elevance Health by 42.2% during the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after buying an additional 27 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ELV. Guggenheim raised their price objective on Elevance Health from $399.00 to $455.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Barclays lowered their target price on Elevance Health from $480.00 to $457.00 and set an “overweight” rating for the company in a report on Thursday, July 16th. Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. UBS Group lifted their price target on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $395.00 price target on shares of Elevance Health in a report on Thursday, July 16th. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $440.90.

Check Out Our Latest Stock Analysis on ELV

Elevance Health Price Performance

Shares of NYSE:ELV opened at $377.39 on Friday. The firm has a market cap of $81.84 billion, a PE ratio of 16.77, a price-to-earnings-growth ratio of 2.18 and a beta of 0.67. The firm’s fifty day moving average is $398.69 and its 200-day moving average is $356.52. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $436.24.

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, topping the consensus estimate of $6.21 by $1.24. The company had revenue of $49.83 billion for the quarter, compared to analysts’ expectations of $48.88 billion. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. Elevance Health’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $8.84 earnings per share. Sell-side analysts predict that Elevance Health, Inc. will post 27.08 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Thursday, September 10th. Elevance Health’s payout ratio is 30.58%.

Insider Buying and Selling at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the sale, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.34% of the company’s stock.

Elevance Health Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.